ImmunityBio Newsroom

ImmunityBio Analyst Ratings

BenzingaNov 19 12:32 ET

ImmunityBio Analyst Ratings

BenzingaNov 12 12:06 ET

IBRX Soars 47% on Initial Trials For Cell Therapy Product

Barron'sOct 25 13:58 ET

EF Hutton Initiates ImmunityBio(IBRX.US) With Buy Rating, Announces Target Price $30

Moomoo NewsOct 23 08:35 ET

EF Hutton Initiates Coverage On ImmunityBio With Buy Rating, Announces Price Target of $30

BenzingaOct 23 07:12 ET

ImmunityBio Analyst Ratings

BenzingaAug 19 12:29 ET

Jefferies Maintains ImmunityBio(IBRX.US) With Buy Rating, Raises Target Price to $8

Moomoo NewsAug 19 08:33 ET

Analysts Offer Insights on Healthcare Companies: Bluebird Bio (BLUE), ImmunityBio (IBRX) and Neurocrine (NBIX)

TipRanksAug 19 08:15 ET

Piper Sandler Maintains ImmunityBio(IBRX.US) With Hold Rating, Cuts Target Price to $4.75

Moomoo NewsAug 19 07:32 ET

Piper Sandler Keeps Their Hold Rating on ImmunityBio (IBRX)

TipRanksAug 19 07:01 ET

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Idexx Laboratories (IDXX) and ImmunityBio (IBRX)

TipRanksMay 6 08:35 ET

ImmunityBio Analyst Ratings

BenzingaApr 29 07:50 ET

Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA), Healthcare Services (HCSG) and ImmunityBio (IBRX)

TipRanksApr 29 07:11 ET

ImmunityBio (IBRX) Gets a Hold From Piper Sandler

TipRanksApr 29 07:08 ET

Analysts Conflicted on These Healthcare Names: Masimo (MASI), ImmunityBio (IBRX) and Madrigal Pharmaceuticals (MDGL)

TipRanksMar 25 06:50 ET

ImmunityBio Analyst Ratings

BenzingaMar 25 06:41 ET

Piper Sandler Reaffirms Their Hold Rating on ImmunityBio (IBRX)

TipRanksNov 14, 2023 07:36 ET

ImmunityBio (IBRX) Gets a Buy From Jefferies

TipRanksMay 15, 2023 09:25 ET

Piper Sandler Downgrades ImmunityBio to Neutral, Lowers Price Target to $4

BenzingaMay 12, 2023 05:27 ET

Jefferies Starts ImmunityBio at Buy With $8 Price Target

MT NewswiresAug 3, 2022 07:30 ET